Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A major drawback of current cartilage and intervertebral disc tissue engineering is that human mesenchymal stem cells (MSCs) from osteoarthritic (OA) patients express type X collagen (COL10), a marker of late-stage chondrocyte hypertrophy (associated with endochondral ossification). Parathyroid hormone (PTH) regulates endochondral ossification by inhibiting chondrocyte differentiation toward hypertrophy. In this study, we investigated the effect of PTH on expression of COL10 in MSCs from OA patients and analyzed the potential mechanisms related to its effect. MSCs were obtained from aspirates from the intramedullary canal of donors undergoing total hip replacement for OA. Expanded cells were then incubated for 0-48  h without (control) or with 100  nM PTH (1-34). Protein expression and phosphorylation were measured by Western blot. Results showed that PTH (1-34) inhibited expression of COL10 in MSCs from OA patients in a time-dependent manner. In parallel, PTH (1-34) stimulated expression of COL2, a marker of chondrogenic differentiation. Results also showed that PTH (1-34) inhibited in a sustained manner the phosphorylation of p38 and AKT protein kinase signaling pathways. Interestingly, the modulation of COL2 and COL10 gene expression was significant as rapidly as after 1  h in the presence of PTH (1-34); changes in the phosphorylation of p38 and AKT were significant only after 6  h. This suggests that while p38 and AKT protein kinase signaling pathways may not be required to initiate the regulation of expression of COL2 and COL10 by PTH (1-34), these pathways may modulate later events necessary for preventing precocious MSC hypertrophy.

Download full-text PDF

Source
http://dx.doi.org/10.1089/ten.TEA.2010.0091DOI Listing

Publication Analysis

Top Keywords

pth 1-34
24
p38 akt
12
parathyroid hormone
8
type collagen
8
mesenchymal stem
8
stem cells
8
osteoarthritic patients
8
endochondral ossification
8
pth
8
expression col10
8

Similar Publications

Background: Vitamin D insufficiency is increasingly recognized as a significant and underlying contributor to a wide range of musculoskeletal disorders, particularly in gastrointestinal (GI) and endocrine health. The study aims to determine the clinical relationship between vitamin D status and the severity of GI symptoms, while also assessing the impact of related endocrine disturbances.

Methods: A cross-sectional study was conducted involving 120 adult patients with GI problems, including constipation, bloating, irritable bowel syndrome (IBS), and dyspepsia in a tertiary care hospital over a six-month duration.

View Article and Find Full Text PDF

Research conducted over the last 15 years indicates that cAMP is generated not just from the plasma membrane but also from intracellular compartments, particularly in endosomes, where receptors are redistributed during the endocytosis process. This review centers on the parathyroid hormone type 1 receptor (PTHR) as a model for a peptide hormone GPCRs that generates cAMP from various locations with distinct duration and pharmacological effectiveness. We discuss how structural dynamics simulations aid in designing ligands that induce cAMP location bias, ultimately answering how the spatiotemporal generation of cAMP affects pharmacological responses mediated by the PTHR.

View Article and Find Full Text PDF

Intermittent PTH treatment has been used as both an osteoanabolic treatment in osteoporosis and a hormone replacement in hypoparathyroidism for many years. This scoping review compiles and reinterprets studies using histomorphometry supported by bone turnover markers to investigate the elusive cellular effect of intermittent PTH treatment locally within the bone, while illuminating knowledge gaps. Intermittent PTH increases both osteoclast and osteoblast activity within the first 6 months of treatment.

View Article and Find Full Text PDF

Rationale: Brown tumor (osteitis fibrosa cystica) is a benign bone lesion associated with hyperparathyroidism that can affect multiple bones in patients with end-stage renal disease (ESRD).

Patient Concerns: We present the case of a 32-year-old female with ESRD on maintenance hemodialysis who experienced body aches, muscle weakness, constipation, and mood swings for 3 months.

Diagnoses: Initial tests revealed elevated parathyroid hormone (PTH), serum calcium, and phosphorus levels.

View Article and Find Full Text PDF

The Application of Assay- and Age-Specific Parathyroid Hormone (PTH) Reference Intervals Decreases the Diagnosis of Normocalcaemic Primary Hyperparathyroidism and Improves Diagnostic Concordance of PTH Assays.

Horm Metab Res

September 2025

Clinical Biochemistry, The Royal Wolverhampton NHS Trust, Black Country Pathology Services, Wolverhampton, United Kingdom of Great Britain and Northern Ireland.

Parathyroid hormone (PTH) assays are not standardized and therefore PTH results are interpreted using manufacturer-provided assay-specific reference intervals. Assay-specific PTH reference intervals, however, do not account for between-assay differences and lead to discordance in the diagnosis of normocalcaemic primary hyperparathyroidism (NCPHPT). PTH increases with age independent of vitamin D, renal function, phosphate and ionized calcium.

View Article and Find Full Text PDF